EANS-DD: AGENNIX AG
Notification concerning transactions by persons performing
managerial responsibilities pursuant to section 15a of the WpHG
-------------------------------------------------------------------------------- Notification concerning transactions by persons discharging managerial responsibilities pursuant to section 15a of the WpHG, transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement. --------------------------------------------------------------------------------
Details of the person subject to the disclosure requirement: --------------------------------------------------------------------------------
Person, triggering the disclosure:
-----------------------------
Name: dievini Hopp BioTech holding GmbH & Co. KG
(Legal person, company or institution)Reason for the disclosure requirement: ------------------------------ Reason: Legal person, company or institution closely associated Relationship: To a person performing managerial responsibilities
Person performing managerial responsibilities, triggering the disclosure requirement:
--------------------------------------------------------------------------------
Position: Member of an administrative or supervisory body
Details of the transaction:
--------------------------------------------------------------------------------
Transaction:
------------
Description of financial instrument: Ordinary bearer shares with no par value
ISIN: DE000A1A6XX4
Type of transaction: sales
Date: 26.11.2010
Currency: Euro
Price: 3.81000
No of items: 688112
Total amount traded: 2,621,706.72000
Place: OTC
Explanation: The shares were sold to an indirect parent company of
dievini BioTech holding GmbH & Co. KG, that also previously
held shares in Agennix AG. The sale by dievini Hopp BioTech
holding GmbH & Co. KG is attributed to the named members of
the managing and supervisoring bodies (Prof. von Bohlen und
Halbach as a member of the Management Board and Prof.
Hettich as a member of the Supervisory Board).Further inquiry note: ----------------- Investor Relations & Corporate Communications Tel.: +49 (0) 89 8565 2693 E-Mail: ir@agennix.com
Issuer subject to the publication requirement: --------------------------------------------------------------------------------
end of announcement euro adhoc --------------------------------------------------------------------------------
Further inquiry note:
Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade
Original-Content von: AGENNIX AG i.L., übermittelt durch news aktuell